Cure My Disease

Don't miss your cure!

 Log in / Sign up

Three-Drug antifungal cocktails put to the test against stubborn skin fungus

NCT ID NCT07816510

Disease control Sponsor: Chittagong Medical College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Dermatophytosis, a common fungal skin infection, often becomes chronic and resists standard treatment. Researchers are comparing three oral antifungal combinations: terbinafine plus fluconazole, terbinafine plus itraconazole, and terbinafine plus voriconazole. The trial enrolls 138 adults with refractory dermatophytosis to measure cure rates and side effects over six weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oral terbinafine combined with fluconazole, itraconazole, or voriconazole
What this could lead to
If one combination works better, doctors could have clearer guidance for treating stubborn fungal skin infections that resist standard therapy.
What could go wrong
This is a small study in one region, and combining antifungals may raise the risk of liver or other side effects. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

138 people

The number who actually took part.

Started

Mar 2021

Finished

Aug 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with refractory dermatophytosis (patients who did not respond to routine treatment, relapsed soon after stoppage of treatment, or those having persistent dermatophytes infection) * Patients of both sexes with age 18 years and above. Exclusion Criteria: * Refused to participate in the study. * Pregnancy and lactation. * Any history of a drug reaction or allergy to any of the four drugs, * Any significant abnormality in complete blood counts (CBC), liver function test (LFT), renal function test (RFT) and electrocardiogram (ECG) * Patients with comorbidities like cardiac disorder, liver disorder, renal disorder. * Patients with an associated bacterial co-infection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dermatophytosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dermatophytosis fungal infectious disease Tinea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dermatophytosis

Contacts and locations

Locations

  • Chittagong Medical College

    Chittagong, 4203, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.